Blog dedicated to the continuous education in Gynecology and Endocrinology

 

Suggested Readings

  1. Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. Gjønnaess H. Acta Obstet Gynecol Scand. 1994 May;73(5):407-12.
  2. Ultrasonographic guided ovarian stroma hydrocoagulation for ovarian stimulation in polycystic ovary syndrome. Ramzy AM, Al-Inany H, Aboulfoutouh I, Sataar M, Idrees OA, Shehata MH Acta Obstet Gynecol Scand. 2001 Nov;80(11):1046-50
  3. Ovarian size and response to laparoscopic ovarian electro-cauterization in polycystic ovarian disease.Alborzi S, Khodaee R, Parsanejad ME. Int J Gynaecol Obstet. 2001 Sep;74(3):269-74.
  4. more

Post to Twitter Post to Facebook

Antimullerarian hormone levels after laparoscopic endoemtrioma stripping surgery

Ercan Cihangir DGYE-2009-0146.r1[ID 463722] 5 PAG

Objective: To evaluate whether a change takes place in AMH levels reflecting the ovarian reserve after laparoscopic endometrioma stripping surgery and to demonstrate if there is any correlation between AMH levels and the sizes of endometriomas. more

Post to Twitter Post to Facebook

Expression of Vascular Endothelial Growth Factor mRNA in Human Leiomyomas

Lewicka DGYE-2009-0156.r1[ID 463724] 5 PAG

Growth factors play a major role in the pathogenesis of uterine myomas. The aim of this study was to evaluate vascular endothelial growth factor (VEGF) mRNA expression during leiomyoma growth at different phases of the menstrual cycle with RT-PCR. We studied 56 patients: 43 with myomas, 13 with healthy myometriums. In patients with myomas (secretory phase), VEGF expression was 2.82 times higher than in control patients (P<0.05). In patients with myomas (phase I), VEGF expression was 2.53 times higher (p<0.05) than in control patients. For all patients with myomas, those that were in menopause had 1.52 times higher VEGF expression than those that menstruated. For patients with healthy myometriums, those that were in menopause had 1.97 times higher VEGF expression than those that menstruated. A comparison of all the patients in menopause revealed that VEGF expression was 2.03-fold higher in those with myomas than in those with healthy myometriums. Conclusions: We observed the highest VEGF mRNA expression in women with myomas that were in menopause. Among menstruating patients, VEGF expression was significantly higher in those with myomas compared to those with a healthy myometrium. This suggested that VEGF may play a significant role in the pathogenesis of uterine myomas.

Post to Twitter Post to Facebook

• May, 2010 •

Editorial

Dear GynEndocrinologists,
We made it to May and the summer is approaching in the northern part of the Globe, although in many spots of this World it doesn’t seem so! All the worst for the crazy interconnections between the weather and our hormones, that may risk to erupt such as that unpronounceable volcano in Iceland… Damn! Traveling is growingly more hectic between endless airport safety measures, strikes, economy crisis blues and now… even volcanoes! more

Post to Twitter Post to Facebook

Suggested Readings

  1. PCOS and Urethrovaginal Space: 3-D Volumetric and Vascular Analysis. Battaglia C, Nappi RE, Mancini F, Alvisi S, Del Forno S, Battaglia B, Venturoli S. J Sex Med. 2010 Jan 6.
  2. Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. Agrawal R, Sladkevicius P, Engmann L, Conway GS, Payne NN, Bekis J, Tan SL, Campbell S, Jacobs HS. Hum Reprod. 1998 Mar;13(3):651-5.
  3. Utero-ovarian arterial blood flow and hormonal profile in patients with polycystic ovary syndrome.Vrtacnik-Bokal E, Meden-Vrtovec H. Hum Reprod. 1998 Apr;13(4):815-21.
  4. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters. Carmina E, Orio F, Palomba S, Longo RA, Lombardi G, Lobo RA. Fertil Steril. 2005 Aug;84(2):413-9.
  5. Doppler study of the uterine arteries and ovarian stroma in patients with polycystic ovary syndrome. Resende AV, Mendes MC, Dias de Moura M, Mendonça HC, Gomes Premoli AC, Reis RM, Berezowski AT. Gynecol Obstet Invest. 2001;52(3):153-7.
  6. The role of color Doppler imaging in the diagnosis of polycystic ovary syndrome. Battaglia C, Artini PG, D’Ambrogio G, Genazzani AD, Genazzani AR. Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):108-13.
  7. The effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome. Ozcimen EE, Uckuyu A, Ciftci FC, Zeyneloglu HB. Arch Gynecol Obstet. 2009 Aug;280(2):263-9.
  8. Ultrasound in polycystic ovary syndrome–the measuring of ovarian stroma and relationship with circulating androgens: results of a multicentric study. Fulghesu AM, Angioni S, Frau E, Belosi C, Apa R, Mioni R, Xamin N, Capobianco GP, Dessole S, Fruzzetti F, Lazzarini V, Minerba L, Melis GB, Lanzone A. Hum Reprod. 2007 Sep;22(9):2501-8.
  9. Use of exogenous gonadotropins in anovulatory women: a technical bulletin. Practice Committee of American Society for Reproductive Medicine. Fertil Steril. 2008 Nov;90(5 Suppl):S7-12.
  10. Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Berga SL, Loucks TL. Ann N Y Acad Sci. 2006 Dec;1092:114-29.
  11. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. ACOG Committee on Practice Bulletins–Gynecology. Obstet Gynecol. 2009 Oct;114(4):936-49.
  12. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Fertil Steril. 2009 Dec;92(6):1966-82.
  13. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. Fertil Steril. 2009 Feb;91(2):456-88.
  14. Consensus on infertility treatment related to polycystic ovary syndrome. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Fertil Steril. 2008 Mar;89(3):505-22.
  15. The evaluation and treatment of androgen excess. Practice Committee of the American Society for Reproductive Medicine. Fertil Steril. 2006 Nov;86(5 Suppl 1):S241-7.
  16. Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome. Practice Committee of the American Society for Reproductive Medicine. Fertil Steril. 2006 Nov;86(5 Suppl 1):S221-3.
  17. Current evaluation of amenorrhea. Practice Committee of the American Society for Reproductive Medicine. Fertil Steril. 2006 Nov;86(5 Suppl 1):S148-55.
  18. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. Endocr Pract. 2005 Mar-Apr;11(2):126-34.

Post to Twitter Post to Facebook

© International Society of Gynecological Endocrinology - Privacy Policy